NCT04122586 is a NA clinical trial of Tongxieyaofang(granule) in IBS (Irritable Bowel Syndrome), sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences.

Who is sponsoring NCT04122586?

NCT04122586 is sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences.

What drugs are being tested in NCT04122586?

Interventions in NCT04122586: Tongxieyaofang(granule).

What condition does NCT04122586 study?

NCT04122586 studies IBS (Irritable Bowel Syndrome).

Is NCT04122586 still recruiting?

NCT04122586 is currently status unknown. Last updated 2 January 2020.

Last reviewed 2020-01-02 · How we verify

NCT04122586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mechanism of PERK - eIF2a Pathways in Intestinal Mucosal Barrier of IBS-D and the Role "Metabolism Ingredients" of Tongxieyaofang

Status unknown NA Last updated 2 January 2020

What this trial tests

NA trial testing Tongxieyaofang(granule) in IBS (Irritable Bowel Syndrome) in 60 participants. Status unknown.

Timeline

1 August 2018

Primary endpoint
31 December 2020

31 December 2021

Quick facts

Lead sponsor	Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	60
Start date	1 August 2018
Primary completion	31 December 2020
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Tongxieyaofang(granule) — full drug profile →

Conditions studied

IBS (Irritable Bowel Syndrome) — all drugs for IBS (Irritable Bowel Syndrome) →

Sponsor

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Who can join

Adults 18 to 70, any sex, with IBS (Irritable Bowel Syndrome). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diarrhea irritable bowel syndrome(IBS-D）has seriously affected health and quality of life of patients.It may be important pathogenesis in development and recurrence of the process of IBS-D,excessive endoplasmic reticulum stress (ERS) activated PERK(proteinkinaseR-like ERkinase，PERK)-eIF2a(eukaryotic translation initiation factor 2 alpha,eIF2a) pathway and damaged intestinal mucosal epithelial Barrier. Tongxieyaofang(TXYF) had obtained satisfactory effect in treating IBS-D in clinic and previous study, but it is unknown that herbal formula how to work.This project applies metabolomics method to detect plasma,urine and stool metabolites for patients before and after treatment, to determine the effects of the"multiple ingredients"of TXYF in body.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Unfolded protein response in endoplasmic reticulum stress associated with retinal degenerative diseases: A promising therapeutic target.
Zhang H, Mu Y, Li H, Li X. · · 2026 · cited 4× · PMID 40537005 · DOI 10.4103/nrr.nrr-d-24-01124
Endoplasmic reticulum stress in disease pathogenesis: its implications for therapy.
Wei S, Zhang N, Zhang H, Chen Z, et al · · 2026 · PMID 41986307 · DOI 10.1038/s41392-026-02600-z

Verify or expand the search:

Other recruiting trials for IBS (Irritable Bowel Syndrome)

Currently open trials in the same condition.

NCT07168434 — Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome · Phase 3 · recruiting
NCT06889779 — Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms · NA · recruiting
NCT06757491 — Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea · NA · recruiting
NCT07534930 — Personalised Multidisciplinary Treatment in Moderate to Severe IBS · NA · active not recruiting

Other Xiyuan Hospital of China Academy of Chinese Medical Sciences trials

Trials by the same sponsor.

NCT07518420 — Clinical Efficacy Evaluation of Chaizhi Hewei Decoction in the Treatment of Non-Erosive Reflux Disease With Liver-Stomac · NA · not yet recruiting
NCT06845254 — Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrom · Phase 3 · not yet recruiting
NCT06618495 — Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome · Phase 1, PHASE2 · completed
NCT06311890 — Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderat · Phase 2 · recruiting
NCT05638672 — COVID-19 Huashi Baidu Formula Clinical Study · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04122586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiyuan Hospital of China Academy of Chinese Medical Sciences
Last refreshed: 2 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04122586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing